Rodrigo González
Pontificia Universidad Católica de Chile · 69 works · 624 citations · h-index 13
Top works
- BRIM-2: An open-label, multicenter phase II study of vemurafenib in previously treated patients with BRAF V600E mutation-positive metastatic melanoma.
- 3303 Efficacy and safety in key patient subgroups of nivolumab (NIVO) alone or combined with ipilimumab (IPI) versus IPI alone in treatment-naïve patients with advanced melanoma (MEL) (CheckMate 067)
- Immunotherapy of Advanced Malignancy by Direct Gene Transfer of an Interleukin-2 DNA/DMRIE/DOPE Lipid Complex: Phase I/II Experience
- A phase II, randomized, open-label study evaluating the antitumor activity of MEDI-522, a humanized monoclonal antibody directed against the human alpha v beta 3 (avb3) integrin, ± dacarbazine (DTIC) in patients with metastatic melanoma (MM)
- Phase IB Study of Vemurafenib in Combination with the Mek Inhibitor, GDC-0973, in Patients (PTS) with Unresectable or Metastatic BRAFV600 Mutated Melanoma (BRIM7)
- Effect of a Low-Protein Diet on Urinary Albumin Excretion in Uremic Patients
- Vemurafenib and Cobimetinib Potently Inhibit Ps6 Signaling in Brafv600 Mutation–Positive Locally Advanced or Metastatic Melanoma from Brim7 Study
- Biomarkers as predictors of renal damage in neonates undergoing cardiac surgery
- Treatment of patients with metastatic melanoma with bryostatin-1 - phase II study
- A phase III randomized trial of adjuvant biochemotherapy (BC) versus interferon-α-2b (IFN) in patients (pts) with high risk for melanoma recurrence
- Phase II trial of ABI-007 (Abraxane) in previously treated and chemotherapy na??ve patients with metastatic melanoma
- Factors That Predict Duration of Delayed Graft Function in Cadaveric Kidney Transplantation
- Initial Experience in Chile with Stent Implantation in the Right Ventricle Outflow Tract in High-Risk Patients with Tetralogy of Fallot
- Osteitis caused by bacille Calmette-Guérin vaccination: an emergent problem in Chile?
- Duration of Delayed Graft Function Is an Important Predictor of 1-Year Serum Creatinine
- Phase Ib/Ii Study of Lee011 (Cdk4/6 Inhibitor) and Lgx818 (Braf Inhibitor) in Braf-Mutant Melanoma
- Open-label, multicenter, phase II trial of ABI-007 in previously treated and previously untreated patients with metastatic malignant melanoma
- Phase 2 trial of talabostat and cisplatin in patients with stage IV melanoma
- A phase II study of tasisulam sodium (LY573636) as second-line treatment for patients with unresectable or metastatic melanoma.
- Phase II Trial of Piritrexim and DTIC Using an Alternating Dose Schedule in Metastatic Melanoma